Abstracts tagged "infliximab"

Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Grant W. Cannon¹, Scott L. DuVall², Candace L. Hayden³, Liron Caplan⁴, Jeffrey R. Curtis⁵, Kaleb Michaud⁶, Ted R. Mikuls⁷, Andreas M. Reimold⁸, David H. Collier⁹, George Joseph⁹, David J. Harrison⁹ and Brian C. Sauer¹⁰, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³Epidemiology, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁵Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Epdemiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…
Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Bente Glintborg^1,2, Bjorn Gudbjornsson^3,4, Niels Steen Krogh⁵, Emina Omerovic², Natalia Manilo⁶, Mette Holland-Fischer⁷, Hanne M. Lindegaard⁸, Anne Gitte Loft⁹, Henrik Nordin¹⁰, Laura Johnsen¹¹, Sussi Flejsborg Oeftiger¹², Annette Hansen¹³, Claus Rasmussen¹⁴, Gerdur Grondal¹⁵, Árni Jón Geirsson¹⁶ and Merete Lund Hetland^1,2,17, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ¹⁰Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹¹Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, ¹²Department of Rheumatology, Køge Hospital, Køge, East Timor, ¹³Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ¹⁴Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹⁵Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting
Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Denis Choquette¹, Michael Starr², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Jude F. Rodrigues⁶, Dalton E. Sholter⁷, Maqbool K. Sheriff⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Allen J. Lehman¹⁰, Susan M. Otawa¹⁰, Francois Nantel¹¹ and May Shawi¹², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷Rheumatology Associates, Edmonton, AB, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
Abstract Number: 2320 • 2013 ACR/ARHP Annual Meeting
Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis
Xiaomei Leng¹, Weiguo Xiao², Xiaochun Zhu³, Zhonghui Xu¹, Wei Yu¹, Jing Lu², Jiakai Wang², Xiaoru Xia³, Yongji Li³, Yi Liu⁴, Yi Zhao⁴, Honghao Tang⁵, Dongbao Zhao⁶, Yeqing Shi⁶, Huji Xu⁷, Jun Bao⁷, Lin Chen⁷, Ling Lin⁷, Ling Zhou⁷, Guoqiang Chen⁸, Weihong Zhang⁸ and Yan Zhao¹, ¹Peking Union Medical College Hospital, Beijing, China, ²The First Hospital of China Medical University, Shenyang, China, ³The First Hospital of Wenzhou Medical College, Wenzhou, China, ⁴Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁵West China Hospital of Sichuan University, Chengdu, China, ⁶Changhai Hospital of Shanghai, Shanghai, China, ⁷Shanghai Changzheng Hospital, Shanghai, China, ⁸The First People’s Hospital of Foshan, Foshan, China
Background/Purpose: To evaluate the efficacy of treatment with infliximab on joint inflammation and bone erosion in rheumatoid arthritis (RA) patients using ultrasonography. Methods: 80 eligible…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 2033 • 2012 ACR/ARHP Annual Meeting
Infliximab Is an Effective Therapy in Pediatric Renal Sarcoidosis
Elisa Wershba¹, Laura Lewandowski¹, Heather Van Mater² and C. Egla Rabinovich¹, ¹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Duke Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Renal sarcoidosis is an unusual form of a rare multisystem disease, and there is little data to guide therapy. The cytokines implicated in…
Abstract Number: 1677 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children
Matthew L. Stoll¹, Anthony B. Morlandt², Suwat Teerawattanapong², Daniel Young³, Peter D. Waite⁴ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL, ³Radiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Temporomandibular joint (TMJ) arthritis occurs in as much as 80% of children with juvenile idiopathic arthritis (JIA) and can result in substantial facial deformity.…
Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Maria Victoria Hernández¹, Miguel A. Descalzo², Juan D. Cañete¹, Raimon Sanmarti³ and BIOBADASER Study Group⁴, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Research Unit. Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
Abstract Number: 1314 • 2012 ACR/ARHP Annual Meeting
Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², James E. Middleton², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Akira Sagawa³, Takeo Sakurai⁴, Hiroaki Matsuno⁵, Tomomaro Izumihara⁶, Eisuke Shono⁷, Kou Katayama⁸, Toyomitsu Tsuchida⁹, Mitsuyoshi Iwahashi¹⁰, Tomomi Tsuru¹¹ and Motohiro Oribe¹², ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁴Inoue Hospital, Takasaki, Japan, ⁵Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁶Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ⁷Shono Rheumatology Clinic, Fukuoka, Japan, ⁸Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ⁹Tsuchida Clinic, Chiba, Japan, ¹⁰Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ¹¹PS Clinic, Fukuoka, Japan, ¹²Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA…
Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting
The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis
Hideto Kameda¹, Takahiko Kurasawa¹, Hayato Nagasawa², Koichi Amano³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, ³Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…
Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Mathieu Verdet¹, Clément Guillou², Marie-Laure Potier², Martine Hiron², Fabienne Jouen³, Olivier Boyer⁴, Thierry Lequerré⁵ and Olivier Vittecoq⁶, ¹Rheumatology, Rouen University Hospital, Bois Guillaume, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Immunology, Rouen University Hospital, Rouen Cedex, France, ⁴Immunology, INSERM U905, University of Rouen, Rouen, France, ⁵Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting
Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results
Anjali Patwardhan¹, Kelly A. Rouster-Stevens², Harry L. Gewanter³, Grant D. Syverson⁴, Renee F. Modica⁵, Kara M. Schmidt⁶ and Charles H. Spencer⁷, ¹Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ²Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, ³Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, ⁴Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, ⁵Pediatric Rheumatology, University of Florida, Gainesville, FL, ⁶Pediatric Rheumatology, Univ of Louisville, Louisville, KY, ⁷Rheumatology, Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders. Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
Abstract Number: 211 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review
JA Martinez-Lopez Sr.¹, J. Graña Sr.², Santiago Muñoz-Fernandez³, I. Rua-Figueroa⁴, José M. Pego-Reigosa⁵, Estíbaliz Loza Sr.⁶ and SER group for the study of systemic autoimmune diseases⁷, ¹Fundacion Jimenez Diaz, Madrid, Spain, ²Hospital Juan Canalejo, Spain, ³Unit Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁴Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, ⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ⁶Research Unit. Sociedad Española de Reumatología, Madrid, Spain, ⁷Madrid
Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].